Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
0.4239
+0.0029 (0.69%)
At close: Apr 17, 2026, 4:00 PM EDT
0.4285
+0.0046 (1.09%)
After-hours: Apr 17, 2026, 7:44 PM EDT
Femasys Revenue
In the year 2025, Femasys had annual revenue of $2.29M with 40.77% growth. Femasys had revenue of $813.39K in the quarter ending December 31, 2025, with 39.86% growth.
Revenue (ttm)
$2.29M
Revenue Growth
+40.77%
P/S Ratio
11.16
Revenue / Employee
$42,469
Employees
54
Market Cap
25.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.29M | 664.20K | 40.77% |
| Dec 31, 2024 | 1.63M | 557.14K | 51.97% |
| Dec 31, 2023 | 1.07M | -134.25K | -11.13% |
| Dec 31, 2022 | 1.21M | 26.53K | 2.25% |
| Dec 31, 2021 | 1.18M | 141.77K | 13.66% |
| Dec 31, 2020 | 1.04M | 108.86K | 11.72% |
| Dec 31, 2019 | 929.06K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harvard Bioscience | 86.55M |
| Retractable Technologies | 38.27M |
| Bionano Genomics | 28.51M |
| Precision Optics Corporation | 24.42M |
| Jin Medical International | 20.69M |
| Nephros | 18.79M |
| Ekso Bionics Holdings | 12.80M |
| Milestone Scientific | 8.97M |
FEMY News
- 19 days ago - Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination - GlobeNewsWire
- 3 months ago - Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care - GlobeNewsWire
- 4 months ago - Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - GlobeNewsWire
- 5 months ago - PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Business Wire
- 5 months ago - Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million - GlobeNewsWire
- 6 months ago - Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo - GlobeNewsWire